DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR MARKET ANALYSIS

Regional Analysis

Global Dual Specificity Protein Kinase Ttk Inhibitor Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global dual specificity protein kinase Ttk inhibitor market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global dual specificity protein kinase Ttk inhibitor market is expected to witness significant growth in the near future, driven by the growing number of protein kinase Ttk inhibitors approvals by U.S. FDA. For instance, in December 2021, NTRC, a Dutch-based precision medicine company specializing in the discovery and development of innovative kinase inhibitors to treat cancer patients, announced that the U.S. Food and Drug Administration (FDA) had approved an Investigational New Drug (IND) application for the novel kinase inhibitor BAL0891, a mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division, leading to tumor cell death. BAL0891 was developed by NTRC and licensed to Basilea Pharmaceutica International Ltd., a commercial stage biopharmaceutical company which is headquartered in Switzerland.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa